Additional cytogenetic abnormalities (ACA) are considered a high risk feature in chronic
myeloid leukemia (CML). However, its prognostic significance at the time of diagnosis in the …

Clonal cytogenetic evolution with additional chromosomal abnormalities (ACAs) in chronic
myelogenous leukemia (CML) is generally associated with decreased response to tyrosine …

Background: Chronic Myeloid Leukemia's (CML) treatment was optimized since the
development of tyrosine kinase inhibitors (TKI) and an increased overall survival during TKI …

Achieving major molecular response (MMR) with BCR:: ABL1 tyrosine kinase inhibitors
(TKIs) is associated with lower chances of progression to advanced phase disease and …

Additional chromosomal abnormalities (ACAs) in Philadelphia-positive cells have been
reported in∼ 5% of patients with newly diagnosed chronic myeloid leukemia (CML) in …

We analyzed the association between achievement of early complete cytogenetic response
(CCyR) and event-free survival (EFS) and overall survival (OS) in patients with newly …

Currently used treatment of CML dramatically improved the prognosis of disease. However,
additional chromosome aberrations (ACA/Ph+) are still one of the adverse prognostic …

Most patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with
tyrosine kinase inhibitors (TKI) achieve complete cytogenetic response (CCyR). An …

Somatic mutations commonly detected in a variety of myeloid neoplasms have not been
systematically investigated in chronic myeloid leukemia (CML). We performed targeted deep …

Second-generation tyrosine kinase inhibitors are effective in Philadelphia chromosome–
positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) …